Correction: The therapeutic effect of radiotherapy combined with systemic therapy compared to radiotherapy alone in patients with simple brain metastasis after first-line treatment of limited-stage small cell lung cancer: a retrospective study

Xinyu Gao, Tingting Liu, Min Fan, Hongfu Sun, Shixuan Zhou, Yuxin Zhou, Haolin Zhu, Ru Zhang, Zhanyuan Li, Wei HuangWorld 2024 · DOI · OpenAlex

Introduction

In the field of oncology, the precision of reported data is paramount for guiding clinical practice. This article serves as a formal correction to a retrospective study investigating the therapeutic effects of radiotherapy combined with systemic therapy versus radiotherapy alone in patients with limited-stage small cell lung cancer (LS-SCLC) who developed simple brain metastases following first-line treatment. The original publication contained significant typographical errors in the reported Hazard Ratios (HR), which necessitated an official erratum to ensure the integrity of the clinical findings.

The Significance of the Hazard Ratio Correction

The primary focus of this correction is the adjustment of the Hazard Ratio (HR) values reported in both the univariate analysis and the survival analysis of the matched dataset. In clinical research, the HR is a measure of how often a particular event (such as death or disease progression) happens in one group compared to how often it happens in another group over time.

In the original text, the HR for combined therapy versus monotherapy was reported as 0.063. From a clinical perspective, an HR of 0.063 suggests a 93.7% reduction in the risk of the event—a level of efficacy that is virtually unprecedented for systemic therapies in small cell lung cancer. Such a figure would likely be viewed with skepticism by the medical community as it deviates significantly from established clinical norms. The corrected value of 0.630 represents a 37% reduction in risk. While this still indicates a statistically significant and clinically meaningful benefit for the combination of systemic therapy and radiotherapy, it aligns much more realistically with the expected outcomes for this patient population.

Updated Quantitative Results

The authors have updated the original article to reflect the following corrections:

1. Univariate Analysis (Table 3)

The HR for "Monotherapy vs. Combined therapy" has been corrected from 0.063 to 0.630. This change ensures that the tabular data accurately reflects the statistical analysis performed on the patient cohort.

2. Results Section (Matched Dataset)

In the narrative description of the survival analysis for the matched dataset, two specific errors were addressed:

  • The HR for combined therapy was corrected from 0.036 to 0.630.
  • The HR for Prophylactic Cranial Irradiation (PCI) was corrected from a formatting error ("HR=0. 0.369") to the precise value of 0.369.

Clinical Implications and Data Integrity

Small cell lung cancer is characterized by its aggressive nature and high propensity for brain metastasis. Determining the optimal sequence and combination of radiotherapy and systemic therapy is a critical area of ongoing research. While the typographical errors were substantial (representing a ten-fold difference in the reported effect size), the fundamental conclusion of the study remains intact: combined modality therapy appears to offer a survival advantage over radiotherapy alone in this specific subset of LS-SCLC patients.

This correction underscores the necessity of rigorous peer review and the importance of "plausibility checks" during the data entry and analysis process. For clinicians and researchers utilizing this study to inform future trials or treatment protocols, it is essential to reference the corrected HR of 0.630 to maintain an accurate understanding of the treatment's relative benefit.

Conclusion

The formal amendment of these values preserves the internal validity of the research and ensures that the published record reflects the true findings of the retrospective analysis. The authors have confirmed that these changes do not alter the overall conclusions regarding the benefits of combined therapy, but they provide the necessary precision required for evidence-based medicine.

Summary updated

BibTeX
@inproceedings{gao2024correction,
  author = {Xinyu Gao and Tingting Liu and Min Fan and Hongfu Sun and Shixuan Zhou and Yuxin Zhou and Haolin Zhu and Ru Zhang and Zhanyuan Li and Wei Huang},
  title = {{Correction: The therapeutic effect of radiotherapy combined with systemic therapy compared to radiotherapy alone in patients with simple brain metastasis after first-line treatment of limited-stage small cell lung cancer: a retrospective study}},
  booktitle = {World},
  year = {2024},
  doi = {10.1186/s12957-024-03531-1},
}
Figure